https://www.prnewswire.com/news-releases/acurx-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024975.html
https://www.acurxpharma.com/news-media/press-releases
https://www.prnewswire.com/news-releases/acurx-announces-positive-phase-2b-results-showing-100-of-patients-who-had-clinical-cure-with-ibezapolstat-also-had-sustained-clinical-cure-302010978.html
https://www.acurxpharma.com/news-media/press-releases/detail/67/acurx-pharmaceuticals-inc-reports-third-quarter-2023
https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-reports-third-quarter-2023-results-and-provides-business-update-301985362.html
https://www.acurxpharma.com/news-media/press-releases/detail/66/acurx-announces-positive-top-line-ibezapolstat-phase-2
https://www.prnewswire.com/news-releases/acurx-announces-positive-top-line-ibezapolstat-phase-2-efficacy-results-with-96-clinical-cure-rate-in-patients-with-c-difficile-infection-301975406.html
https://www.acurxpharma.com/pipeline/publications
https://www.acurxpharma.com/news-media/press-releases/detail/65/acurx-pharmaceuticals-to-discuss-third-quarter-2023
https://www.prnewswire.com/news-releases/acurx-announces-ibezapolstat-scientific-posters-and-presentations-at-clostpath-2023-and-idweek-2023-scientific-conferences-301961565.html
https://www.biomicamed.com/wp-content/uploads/2021/01/Biomica_Presentation_MicrobiomeMovement2021.pdf
https://www.prnewswire.com/news-releases/global-microbiome-therapeutics-markets-2021-2032-need-for-current-good-manufacturing-practice-cgmp-certified-contract-manufacturing-facilities-301596050.html
https://www.prnewswire.com/news-releases/global-human-microbiome-markets-2019-2030-drugs-companies-therapeutics-diagnostics-case-studies-executive-insights-and-more-300980799.html
https://www.prnewswire.com/news-releases/human-microbiome-therapeutics-market-size-to-grow-by-usd-732-95-million-from-2022-to-2027--north-america-to-account-for-41-of-market-growth---technavio-302027860.html
https://www.prnewswire.com/news-releases/human-microbiome-therapeutics-market-size-to-grow-at-a-cagr-of-30-11-from-2022-to-2027--increase-in-industry-academia-collaboration-for-the-development-of-novel-therapeutics-is-a-major-trend--technavio-301890688.html
https://www.prnewswire.com/news-releases/global-precision-medicine-partnering-terms-and-agreements-2016-2023-unprecedented-access-to-the-deals-and-agreements-entered-into-by-the-worlds-leading-healthcare-companies-301820760.html
https://www.rebiotix.com/
https://microbiotica.com/microbiotica-announces-clinical-trial-collaboration-with-msd-to-evaluate-mb097-in-combination-with-keytruda-pembrolizumab-in-a-phase-1b-clinical-trial-in-melanoma/
https://microbiotica.com/media-centre/news/
https://www.prnewswire.com/news-releases/global-microbiome-therapeutics-market-report-2022-featuring-4d-pharma-enterome-finch-therapeutics-vedanta-bioscience--more-301692404.html
https://microbiotica.com/microbiotica-announces-transition-of-leadership/
https://www.prnewswire.com/news-releases/microbiome-therapeutics-global-market-to-reach-1-billion-by-2026-at-a-26-4-cagr-301650628.html
https://microbiotica.com/immuno-series-uk/
https://www.prnewswire.com/Sitemap_Index_Feb_2022.xml.gz
https://www.prnewswire.com/news-releases/ascentage-pharma-and-clover-biopharmaceuticals-announce-clinical-collaboration-to-evaluate-iap-antagonist-apg-1387-plus-the-recombinant-human-trail-trimer-fusion-protein-scb-313-for-the-treatment-of-peritoneal-carcinomatosis-301441158.html
https://www.prnewswire.com/Sitemap_Index_Jun_2021.xml.gz
https://www.prnewswire.com/Sitemap_Index_Apr_2021.xml.gz
https://www.prnewswire.com/Sitemap_Index_Mar_2021.xml.gz
https://www.prnewswire.com/news-releases/5g-is-on-the-fast-track-spurred-by-covid-19-301110685.html
https://www.prnewswire.com/Sitemap_Index_Jun_2020.xml.gz
https://www.prnewswire.com/news-releases/2020-outlook-into-the-global-omega-3-polyunsaturated-fatty-acids-market-301026878.html
https://www.prnewswire.com/Sitemap_Index_Feb_2020.xml.gz
https://www.prnewswire.com/Sitemap_Index_Sep_2012.xml.gz
https://www.prnewswire.com/news-releases/global-airway-management-devices-market-report-2023-2033-rising-demand-for-advanced-airway-management-devices-driven-by-surgical-surges-and-chronic-illnesses-302029630.html
https://www.prnewswire.com/news-releases/global-educational-furniture-market-analysis-report-2033-a-6-19-billion-industry-by-2028-fueled-by-evolving-classroom-dynamics-enrollment-surge-and-government-initiatives-302029798.html
https://www.prnewswire.com/news-releases/united-states-mobile-medical-imaging-service-market-report-2024-2029-long-term-care-centers-and-palliative-care-drive-demand-302013394.html
https://www.prnewswire.com/news-releases/global-feed-phytogenics-industry-report-2022-and-2023-2030-market-benefits-as-sustainability-gains-prominence-in-animal-feed-industry-302011728.html
https://www.prnewswire.com/news-releases/netherlands-buy-now-pay-later-business-report-2023-a-17-4-billion-market-by-2028-from-8-billion-in-2022-featuring-afterpay-klarna-billink-and-paypal-301997051.html
https://www.prnewswire.com/news-releases/global-nuclear-fusion-technologies-market-expected-to-skyrocket-to-6-8-billion-by-2040--driven-by-technological-advancements-and-private-investment-301983145.html
https://www.rebiotix.com/stool-donor-program/
https://www.prnewswire.com/news-releases/online-distribution-surges-global-superfood-powders-market-adapts-to-changing-consumer-habits-301934811.html
https://www.prnewswire.com/news-releases/global-aromatherapy-diffuser-market-report-2023-increasing-popularity-of-aromatherapy-bolsters-growth-301856881.html
https://www.prnewswire.com/news-releases/unpack-24-tendencias-de-viaje-en-expedia-hoteles-com-y-vrbo-855329728.html
https://adisotx.com/leadership-team/
https://www.smmttx.com/app/uploads/2020/07/20F-2019.pdf
https://www.smmttx.com/app/uploads/2019/12/201912_Fundraise-and-GM-Circular-FINAL.pdf
https://www.smmttx.com/app/uploads/2019/06/2019_Summit-Therapeutics-20-F.pdf
https://www.smmttx.com/app/uploads/2018/06/2016-20F-FINAL.pdf
https://www.smmttx.com/app/uploads/2018/06/Summit-Therapeutics-20F-2018-FINAL-DOCUMENT-FILED-for-website-with-links-and-exhibits.pdf
https://www.smmttx.com/app/uploads/2018/06/2016_RNS_20-ASM-Microbe-Presentation-Alert-FINAL.pdf
https://www.smmttx.com/app/uploads/2018/06/2016_RNS_16-CoM-Patent-Grant-for-Ridinilazole-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2016_RNS_13-ECCMID-Data-FINAL.pdf
https://www.smmttx.com/app/uploads/2018/06/2016_RNS_07-CoDIFy-Microbiome-Topline-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2016_RNS_01-Ridinilazole-EU-Patent-grant-FINAL.pdf
https://www.prnewswire.com/news-releases/ferring-pharmaceuticals-1st-in-class-cdiff-treatment-rebyota-experiences-a-positive-early-launch-ahead-of-potential-competition-according-to-spherix-global-insights-301775185.html
https://www.prnewswire.com/news-releases/microbiome-therapeutics-market-to-reach-973-63-million-by-2030-at-a-31-24-cagr-301634544.html
https://www.prnewswire.com/news-releases/overt-hepatic-encephalopathy-market-is-booming-worldwide-the-market-size-is-supposed-to-increase-at-a-decent-compound-annual-growth-rate-cagr-during-the-study-period-20192032-evaluates-delveinsight-301517636.html
https://www.prnewswire.com/news-releases/could-microbiome-based-therapeutics-fill-the-unmet-need-in-recurrent-clostridioides-difficile-c-diff-treatment-spherix-investigates-301508372.html
https://www.prnewswire.com/news-releases/hepatic-encephalopathy-drugs-in-development-2022---therapeutics-development--assessment-companies-involved-drug-profiles-product-development-milestones-featured-news--press-releases-301503029.html
https://www.prnewswire.com/news-releases/hepatic-encephalopathy-market-to-procure-from-ageing-population-and-increased-rd-investments-anticipated-steady-growth-boost-at-a-cagr-of-5-31-during-the-study-period-20182030--evaluates-delveinsight-301409947.html
https://www.prnewswire.com/news-releases/microbiome-therapeutics-innovation-group-highlights-member-company-activity-at-idweek-2019-300928074.html
https://www.mgb-biopharma.com/wp-content/uploads/BWT03282019.pdf
https://www.prnewswire.com/news-releases/global-microbiome-therapeutics--diagnostics-market-2018-2023---human-therapeutic-and-diagnostic-pipeline-analysis-300713586.html
https://verbbiotics.com/op-ed-whats-new-in-gut-health-and-sports-nutrition/
https://verbbiotics.com/media/
https://www.prnewswire.com/news-releases/gut-health-survey-highlights-need-to-educate-consumers-on-the-gut-microbiome-for-overall-health-301980235.html
https://verbbiotics.com/privacy-policy/
https://verbbiotics.com/impact-of-gut-health-in-the-us/
https://verbbiotics.com/terms-of-use/
https://verbbiotics.com/op-ed-can-postbiotics-be-the-answer-to-athletes-gi-distress/
https://verbbiotics.com/approach/
https://verbbiotics.com/solutions/
https://verbbiotics.com/
https://www.paratekpharma.com/medical-affairs/publications-and-presentations?c79ade26_page=3
https://www.paratekpharma.com/careers
https://www.paratekpharma.com/investor-relations/press-release?i=129131
https://www.paratekpharma.com/investor-relations/press-release?i=127340
https://www.paratekpharma.com/
https://www.paratekpharma.com/conference-years/2023-2024
https://www.paratekpharma.com/about
https://www.paratekpharma.com/medical-affairs/publications-and-presentations?c79ade26_page=7
https://www.prnewswire.com/news-releases/novo-holdings-advances-antimicrobial-resistance-strategy-with-acquisition-of-paratek-pharmaceuticals-301934920.html
https://www.paratekpharma.com/investor-relations/press-release?i=126945
https://www.mgb-biopharma.com/useful-links/
https://www.mgb-biopharma.com/scientific-advisory-board/
https://www.mgb-biopharma.com/mgb-biopharma-successful-end-of-phase-2-meeting-with-fda-for-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridioides-difficile-infection-cdi/
https://www.prnewswire.com/news-releases/mgb-biopharma---successful-end-of-phase-2-meeting-with-fda-for-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridioides-difficile-infection-cdi-301215669.html
https://www.prnewswire.com/news-releases/mgb-biopharma-announces-successful-outcome-from-phase-ii-clinical-study-with-mgb-bp-3--a-potential-new-gold-standard-first-line-treatment-for-clostridium-difficile-infection-cdi-301061497.html
https://www.mgb-biopharma.com/mgb-biopharma-presents-at-invetival-showcase-2019/
https://www.mgb-biopharma.com/mgb-biopharma-to-attend-upcoming-bioeurope-meeting-in-hamburg-on-11-to-13-nov-2019/
https://www.mgb-biopharma.com/mgb-biopharma-announces-promising-phase-iia-clinical-trial-update-for-mgb-bp-3/
https://valneva.com/investors/stock-price/?lang=de
https://valneva.com/?lang=fr
https://valneva.com/press-release/valneva-vaccinates-first-participant-in-pediatric-trial-of-single-shot-chikungunya-vaccine/
https://valneva.com/press-release/valneva-vaccinates-first-participant-in-pediatric-trial-of-single-shot-chikungunya-vaccine/?lang=de
https://valneva.com/unveiling-the-lesser-known-impact-of-climate-change-the-rise-of-mosquito-borne-diseases/
https://valneva.com/events/42nd-annual-j-p-morgan-healthcare-conference/
https://valneva.com/about-us/our-team/?lang=de
https://valneva.com/press-release/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo-bhf-forum-2/?lang=de
https://valneva.com/?lang=de
https://valneva.com/press-release/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo-bhf-forum-2/
https://crestonepharma.com/knowledge-portal/
https://crestonepharma.com/flagella-classifications-and-how-it-benefits-bacteria/
https://crestonepharma.com/category/events/
https://crestonepharma.com/an-overview-of-nontuberculous-mycobacteria-symptoms/
https://crestonepharma.com/peptidoglycan-what-exactly-is-it/
https://crestonepharma.com/why-are-gram-negative-bacteria-harder-to-kill-with-antibiotics/
https://crestonepharma.com/why-it-is-important-to-always-finish-your-antibiotics/
https://crestonepharma.com/presentation-at-the-2022-national-c-diff-advocacy-summit/
https://crestonepharma.com/c-diff-infection-symptoms-an-overview/
https://openbiome.org/feature/openbiome-recognized-as-a-global-health-leader-by-gbc-health/
https://openbiome.org/feature/fda-approval-of-microbiome-based-therapy-expands-access-for-patients-openbiome-continues-distribution-of-fecal-microbiota-transplantation-fmt/
https://openbiome.org/feature/openbiome-welcomes-joanne-kamens-phd-to-board-of-directors/
https://openbiome.org/feature/openbiome-announces-additions-and-transitions-to-board-of-directors/
https://openbiome.org/wp-content/uploads/Order-Form_August-2023.pdf
https://openbiome.org/filling-gaps-in-microbiome-health-research/
https://openbiome.org/wp-content/uploads/MTP-101LFClinicians-Checklist_July2023-.pdf
https://ondinebio.com/investors/aim-rule-26/
https://ondinebio.com/successful-c4-91-raise-supports-ongoing-commercialisation/
https://ondinebio.com/investors/regulatory-news/
https://ondinebio.com/author/amandavanepercy-com/
https://ondinebio.com/steriwave-featured-daily-mail/
https://ondinebio.com/tag/infection-control/
https://ondinebio.com/photodisinfection-recommended-as-standard-of-care/
https://ondinebio.com/category/amr/
https://ondinebio.com/steriwave-named-as-spie-prism-awards-finalist/
https://www.biomicamed.com/pipeline/
https://www.biomicamed.com/
https://www.exeliombio.com/science/fprau-in-immuno-oncology
https://www.exeliombio.com/science/f-prau
https://www.exeliombio.com/
https://www.smmttx.com/press-releases/
https://www.smmttx.com/our-company/business-development/c-difficile-infection/
https://www.smmttx.com/app/uploads/2018/06/ID-Week-2017-CoDIFy2-FINAL.pdf
https://www.prnewswire.com/news-releases/clostridium-difficile-infection-market-to-show-immense-growth-at-a-cagr-of-12-5-during-the-study-period-20192032--delveinsight-301702515.html
https://www.prnewswire.com/news-releases/akeso-inc-announces-collaboration-and-license-agreement-for-up-to-us5-billion-with-summit-therapeutics-to-accelerate-global-development-and-commercialization-of-its-breakthrough-bispecific-antibody-ivonescimab-pd-1vegf-301695787.html
https://www.prnewswire.com/news-releases/microbiome-clinical-trial-pipeline-space-brims-with-novel-emerging-therapies-with-130-key-players-working-in-the-domain--delveinsight-301672552.html
https://www.smmttx.com/app/uploads/2022/10/2022_PR_1020_ID-Week-2022-Results-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/08/2022_PR_0811_Q2-2022-Financial-Results-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/08/2022_PR_0809_Rights-Offering-2022-Completion-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/08/2022_PR_0802_Rights-Offering-2022-Update-_-FINAL.pdf
https://adisotx.com/
https://www.prnewswire.com/Sitemap_Index_Nov_2018.xml.gz
https://www.prnewswire.com/news-releases/2023-microbiome-market-trends-report-2023-market-is-successfully-commercializing-seres-therapeutics-ser-109-and-rebiotixs-rbx-2660-for-recurrent-clostridium-difficile-infection-302029616.html
https://www.prnewswire.com/news-releases/global-serious-games-market-surges-to-11-17-billion-in-2023--fueled-by-integration-of-emerging-technologies-and-growing-demand-for-learning-solutions-301897783.html
https://www.prnewswire.com/news-releases/alltrna-expands-leadership-team-with-appointments-of-chief-scientific-officer-and-chief-technology-officer-301900137.html
https://www.paratekpharma.com/Serio-ASM-Microbe-2023-OMC-NZW-Rabbit-Anthrax-Poster
https://valneva.com/investors/stock-price/?lang=fr
https://valneva.com/about-us/our-team/
https://openbiome.org/2022-annual-report-draft2/
https://openbiome.org/white-paper-patient-evaluation/
https://openbiome.org/about-us/story/
https://openbiome.org/feature/openbiome-supports-fda-committees-endorsement-of-rbx2660-and-affirms-continued-access-to-fecal-microbiota-transplantation/
https://openbiome.org/feature/openbiome-announces-new-collaboration-with-the-university-of-minnesota-to-treat-patients-with-recurrent-c-difficile-infections/
https://ondinebio.com/about/
https://ondinebio.com/tag/press-release/
https://www.acurxpharma.com/news-media/press-releases/detail/70/acurx-announces-positive-comparative-microbiology-and
https://www.prnewswire.com/news-releases/acurx-announces-positive-comparative-microbiology-and-microbiome-data-for-ibezapolstat-from-phase-2b-clinical-trial-in-cdi-patients-302036789.html
https://www.acurxpharma.com/news-media/press-releases?gclid=EAIaIQobChMI8s73qL_N_QIVEOd3Ch3RjQqpEAMYASABEgJ3rvD_BwE
https://www.prnewswire.com/news-releases/optage-and-nanolock-to-enable-nationwide-iot-security-in-japan-301126682.html
https://www.prnewswire.com/news-releases/microbiome-manufacturing-market-size-and-share-to-surpass-187-million-by-2035--roots-analysis-302034675.html
https://verbbiotics.com/solutions/keystone-postbiotic/
https://www.paratekpharma.com/investor-relations/press-release?i=130169
https://www.paratekpharma.com/medical-affairs/publications-and-presentations?c79ade26_page=4
https://www.paratekpharma.com/investor-relations/press-release?i=121405
https://valneva.com/wp-content/uploads/2024/01/Valneva_Company-Presentation_January_2024.pdf
https://ondinebio.com/jp-errico-appointed-chief-financial-officer/
https://ondinebio.com/about/leadership-team/
https://ondinebio.com/successful-c4-91m-raise-supports-ongoing-commercialisation/
https://ondinebio.com/tag/2023/
https://www.acurxpharma.com/news-media/press-releases/detail/69/acurx-to-present-at-the-42nd-annual-j-p-morgan-healthcare
https://www.acurxpharma.com/news-media/press-releases/detail/64/acurx-announces-ibezapolstat-scientific-posters-and
https://www.acurxpharma.com/news-media/press-releases/detail/63/acurx-pharmaceuticals-announces-successful-completion-and
https://www.acurxpharma.com/news-media/press-releases/detail/62/acurx-announces-presentation-and-update-of-its-pol-iiic-rd
https://www.acurxpharma.com/news-media/press-releases/detail/61/acurx-pharmaceuticals-to-present-at-the-h-c-wainwright
https://microbiotica.com/from-laboratory-to-the-clinic-medicine-after-covid/
https://microbiotica.com/anaerobe-2022/
https://microbiotica.com/microbiome-connect-eu/
https://microbiotica.com/on-helix-bio-innovation-in-prevention/
https://microbiotica.com/milner-therapeutics-symposium/
https://valneva.com/wp-content/uploads/2021/07/Chikungunya_ECCMID2021.pdf
https://www.rebiotix.com/wp-content/uploads/microbiome-bile-acid-restoration-consistent-across-three-clinical-trials-rbx2660-recurrent-clostridioides-difficile-infection-combined-analysis-abstract.docx
https://www.rebiotix.com/wp-content/uploads/treatment-success-reducing-recurrent-clostridioides-difficile-infection-investigational-live-biotherapeutic-rbx2660-associated-microbiota-restoration-consistent-evidence-phase-3-clinical-trial-poster.pdf
https://www.rebiotix.com/wp-content/uploads/interim-analysis-phase-3-open-label-study-indicates-safety-efficacy-rbx2660-investigational-live-biotherapeutic-real-world-population-patients-recurrent-clostridioides-difficile-infection-poster.pdf
https://www.rebiotix.com/wp-content/uploads/Rebiotix-Stool-Donor-Welcome.pdf
https://www.rebiotix.com/wp-content/uploads/durable-reduction-clostridioides-difficile-infection-recurrence-microbiome-restoration-after-treatment-rbx2660-results-open-label-phase-2-clinical-trial.pdf
https://www.rebiotix.com/wp-content/uploads/improvement-microbiome-health-index-patients-recurrent-clostridiodes-difficile-infections-rbx2660-treatment-reduction-antimicrobial-resistance-genes-poster.pdf
https://www.rebiotix.com/wp-content/uploads/changing-the-microbiome-patients-successful-outcome-following-microbiota-based-rbx2660-treatment-healthy-subjects-profile-abstract.pdf
https://www.serestherapeutics.com/our-products/VOWST_PI.pdf
https://www.serestherapeutics.com/patients-and-physicians/Expanded_Access.pdf
https://www.serestherapeutics.com/our-products/
https://www.serestherapeutics.com/about-us/
https://www.serestherapeutics.com/patients-and-physicians/
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Hohmann-E-HRQoL-IDWeek-2021-Oral-LB19.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Louie-T-Time-to-Recurrence-IDWeek-2021-Poster-639.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Cohen-SH-Risk-Factors-IDWeek-2021-Poster-634.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/McChalicher-C-Inactivation-ID-Week-2021-Poster-1035.pdf
https://www.smmttx.com/app/uploads/2022/07/2022_PR_0726_Appointment-of-Maky-as-Co-CEO-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/07/2022_PR_0714_Ridinilazole-Update-_-FINAL-1.pdf
https://www.smmttx.com/app/uploads/2022/06/2022_PR_0603_Annual-Shareholders-Meeting-_-FINAL.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=126694
https://www.paratekpharma.com/investor-relations/press-release?i=121391
https://www.paratekpharma.com/investor-relations/press-release?i=119851
https://www.paratekpharma.com/investor-relations/press-release?i=119687
https://www.paratekpharma.com/investor-relations/press-release?i=119663
https://www.mgb-biopharma.com/mgb-biopharma-announces-successful-outcome-from-phase-ii-clinical-study-with-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridium-difficile-infection-cdi/
https://www.mgb-biopharma.com/mgb-biopharma-announces-completion-of-funding-round/
https://www.mgb-biopharma.com/bio-europe-2019/
https://crestonepharma.com/company/
https://openbiome.org/microbiome-education/openbiome-courses/
https://openbiome.org/the-global-microbiome-conservancy-gmbc/gmbc-consortium/
https://www.acurxpharma.com/news-media/press-releases/detail/71/acurx-pharmaceuticals-to-present-at-the-microcap
https://verbbiotics.com/probiotic-efficacy-measurement/
https://verbbiotics.com/about/
https://verbbiotics.com/our-team/
https://www.paratekpharma.com/investor-relations/press-release?i=119290
https://www.paratekpharma.com/investor-relations/press-release?i=117353
https://www.paratekpharma.com/investor-relations/press-release?i=116490
https://www.paratekpharma.com/investor-relations/press-release?i=114568
https://www.paratekpharma.com/investor-relations/press-release?i=113442
https://valneva.com/investors/
https://valneva.com/
https://valneva.com/media-kit/?lang=de
https://crestonepharma.com/antibiotic-antimicrobial-resistance-how-does-it-happen-what-are-the-consequences/
https://ondinebio.com/ondine-unveils-new-research-at-spie-photonics-west/
https://ondinebio.com/investors/corporate-governance/
https://verbbiotics.com/author/brookeb/
https://verbbiotics.com/op-ed-the-untapped-potential-of-postbiotics-why-clarity-is-key/
https://www.paratekpharma.com/investor-relations/press-release?i=97458
https://www.paratekpharma.com/investor-relations/press-release?i=112186
https://www.paratekpharma.com/investor-relations/press-release?i=109979
https://www.paratekpharma.com/investor-relations/press-release?i=101588
https://www.paratekpharma.com/investor-relations/press-release?i=99988
https://www.paratekpharma.com/investor-relations/press-release?i=95911
https://valneva.com/events/guggenheim-healthcare-talks-6th-annual-biotechnology-conference/
https://valneva.com/press-release/valneva-announces-sale-of-priority-review-voucher-for-103-million/
https://valneva.com/press-release/valneva-announces-sale-of-priority-review-voucher-for-103-million/?lang=de
https://valneva.com/wp-content/uploads/2024/01/Valneva_Company-Presentation_February_2024.pdf
https://ondinebio.com/microbiome-research-supports-use-of-steriwave/
https://www.acurxpharma.com/news-media/press-releases/detail/72/acurx-announces-positive-extended-clinical-cure-data-for
https://www.rebiotix.com/wp-content/uploads/microbiome-profile-patients-successful-response-rbx2660-relative-to-placebo-responders-recurrent-c-diff-abstract.pdf
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Halvorsen-E-SER-155-ID-Week-2021-Oral-130.pdf
https://www.smmttx.com/app/uploads/2022/06/2022_PR_0601_New-Officer-Ankur-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2022/05/2022_PR_0511_Q1-2022-Financial-Results-_-FINAL.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=99016
https://valneva.com/wp-content/uploads/2024/02/Valneva_Company-Presentation_February_2024.pdf
https://www.smmttx.com/app/uploads/2022/04/ECCMID2022_02458_RDZ_MoA_poster_portrait_final.pdf
https://www.paratekpharma.com/investor-relations/press-release
https://valneva.com/press-release/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance/?lang=de
https://valneva.com/press-release/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance/
https://openbiome.org/careers/
https://openbiome.org/about-us/team/
https://www.acurxpharma.com/news-media/press-releases/detail/60/acurx-pharmaceuticals-inc-reports-second-quarter-2023
https://valneva.com/events/world-vaccine-congress-washington-2024/
https://valneva.com/wp-content/uploads/2024/02/Valneva_Company-Presentation_February_2024a-v2.pdf
https://valneva.com/events/guggenheim-healthcare-talks-6th-annual-biotechnology-conference/?lang=de
https://crestonepharma.com/what-is-post-convalescent-c-difficile/
https://openbiome.org/publication/donor-screening-for-fecal-microbiota-transplantation-2/
https://openbiome.org/feature/openbiome-ships-70000th-investigational-fmt-to-treat-c-difficile/
https://openbiome.org/fmt-efficacy/
https://www.acurxpharma.com/news-media/press-releases/detail/73/acurx-announces-fda-has-granted-an-end-of-phase-2-meeting
https://www.smmttx.com/app/uploads/2022/01/Summit-8pg-brochure-Digital_V1_01102022.pdf
https://www.smmttx.com/app/uploads/2021/11/1052_IDWeek2021-Summit-therapeutics-ridinilazole-MoA_Final.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_27-06-2018_RNS_30-PhaseOut-Full-Results-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2021_PR_0701_Upcoming-Conference-ECCMID-_-FINAL.pdf
https://verbbiotics.com/solutions/gaba-probiotic/
https://www.mgb-biopharma.com/asm-microbe-2019/
https://valneva.com/events/td-cowen-44th-annual-health-care-conference/
https://valneva.com/press-release/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-conferences/?lang=de
https://valneva.com/press-release/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-conferences/
https://valneva.com/investors/stock-price/
https://valneva.com/press-release/u-s-cdc-advisory-committee-acip-recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq/
https://valneva.com/press-release/u-s-cdc-advisory-committee-acip-recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq/?lang=de
https://valneva.com/media/press-releases/?lang=fr
https://openbiome.org/
https://openbiome.org/the-global-microbiome-conservancy-gmbc/
https://www.acurxpharma.com/news-media/press-releases/detail/74/acurx-pharmaceuticals-inc-to-discuss-fourth-quarter-and
https://www.rebiotix.com/wp-content/uploads/rbx2660-safe-superior-to-antibiotic-treated-controls-preventing-recurrent-clostridium-difficile-abstract.pdf
https://www.smmttx.com/app/uploads/2022/06/2022_PR_0602_Annual-Shareholders-Meeting-_-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/06/2021_PR_0603_Annual-Shareholders-Meeting-_-FINAL.pdf
https://verbbiotics.com/author/celestia/
https://valneva.com/press-release/valneva-to-present-at-upcoming-td-cowen-and-van-lanschot-kempen-healthcare-investor-conferences/?lang=fr
https://valneva.com/press-release/u-s-cdc-advisory-committee-acip-recommends-use-of-valnevas-single-dose-chikungunya-vaccine-ixchiq/?lang=fr
https://crestonepharma.com/
https://ondinebio.com/ondine-starts-first-uk-health-economics-study/
https://www.smmttx.com/app/uploads/2021/11/Blue_2019_RNS_40-CDI-Awareness-Month-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2019_RNS_36-ID-Week-Microbiome-Data-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2019_RNS_31-Stewardship-paper-FINAL.pdf
https://valneva.com/wp-content/uploads/2019/06/Valneva_KOL_Call_Presentation_11_12_2015.pdf
https://www.mgb-biopharma.com/wp-content/uploads/MGB-Biopharma-Biotrinity-2015-Part-3.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_2014_RNS_14-ECCMID-2014-presentations-FINAL.pdf
https://verbbiotics.com/beyond-gut-health-psychobiotics-and-the-gut-brain-axis/
https://valneva.com/press-release/valneva-announces-extension-of-the-interest-only-period-of-its-debt-facility-with-deerfield-and-orbimed/?lang=de
https://valneva.com/press-release/valneva-announces-extension-of-the-interest-only-period-of-its-debt-facility-with-deerfield-and-orbimed/
https://valneva.com/investors/?lang=fr
https://valneva.com/events/td-cowen-44th-annual-health-care-conference/?lang=de
https://ondinebio.com/steriwave-deploying-in-eight-new-sites/
https://www.smmttx.com/app/uploads/2021/11/Blue_2013_RNS_29-Wedbush-Conference-presentation-FINAL.pdf
https://www.smmttx.com/app/uploads/2021/11/Blue_11_RNS_12-ICAAC-Meeting-attendance-FINAL.pdf
https://valneva.com/press-release/valneva-announces-extension-of-the-interest-only-period-of-its-debt-facility-with-deerfield-and-orbimed/?lang=fr
https://valneva.com/press-release/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance/?lang=fr
https://valneva.com/investors/shareholder-structure/?lang=de
https://ondinebio.com/category/infection-management/
https://ondinebio.com/steriwave-study-shows-77-drop-in-antibiotic-use/
https://valneva.com/events/2023-audited-financial-statements/
https://ondinebio.com/category/infection-control/
https://ondinebio.com/first-commercial-adoption-of-steriwave-by-the-nhs/
https://valneva.com/press-release/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo-bhf-forum-2/?lang=fr
https://valneva.com/press-release/valneva-provides-updated-2023-financial-guidance/?lang=fr
https://ondinebio.com/entry-into-icu-market-expands-revenue-potential/
https://www.acurxpharma.com/news-media/presentations?page=2
https://adisotx.com/news-events/
https://www.biomicamed.com/press-releases/biomica-to-present-at-digestive-disease-week-ddw-conference-2024-annual-meeting/
https://www.biomicamed.com/press-releases/biomica-ceo-set-to-engage-in-panel-discussion-at-8th-annual-european-microbiome-movement-summit/
https://www.biomicamed.com/press-releases/biomica-successfully-completes-phase-i-trial-enrollment-for-microbiome-based-immuno-oncology-drug/
https://www.biomicamed.com/press-releases/biomica-ceo-set-to-attend-jp-morgan-healthcare-week-in-san-francisco-january-8-11-2024/
https://www.biomicamed.com/press-releases/biomica-opens-second-site-to-advance-its-immuno-oncology-drug-trials-at-davidoff-center/
https://www.biomicamed.com/press-releases/biomica-announces-interim-positive-results-from-pre-clinical-studies-in-its-irritable-bowel-syndrome-ibs-program/
https://www.biomicamed.com/press-releases/biomica-announces-closing-of-20-million-financing-round-led-by-shanghai-healthcare-capital/
https://www.biomicamed.com/press-releases/biomica-vp-rd-to-present-at-the-pharmabiotics-2023-conference-on-march-21-2023/
https://www.biomicamed.com/press-releases/biomica-ceo-to-participate-in-panel-discussion-at-7th-european-annual-microbiome-movement/
https://www.biomicamed.com/press-releases/biomica-ceo-to-attend-the-jp-morgan-healthcare-week-in-san-francisco-between-january-9-11-2023/
https://www.enterobiotix.com/news/category/Press+Release
https://www.enterobiotix.com/news/category/News
https://www.enterobiotix.com/news/enterobiotix-completes-27m-financing-round
https://www.enterobiotix.com/news/enterobiotix-announces-ibs-trial
https://www.enterobiotix.com/news/phase-2-study-of-microbiome-drug-ebx-102
https://www.enterobiotix.com/news/enterobiotixs-ceo-dr-james-mcilroy-will-be-presenting-at-the-7th-microbiome-movement-drug-summit-boston-us-2022
https://www.enterobiotix.com/news/enterobiotixs-ceo-dr-james-mcilroy-will-be-presenting-at-biotrinity-london-2022
https://www.enterobiotix.com/news/pharma-letter-podcast
https://www.enterobiotix.com/news/enterobiotix-strengthens-executive-team-feb2024
https://www.enterobiotix.com/news/enterobiotix-article-in-modern-medicine
https://www.exeliombio.com/news/exeliom-is-awarded-a-500k-grant-from-the-crohns-and-colitis-foundation
https://www.exeliombio.com/news/exeliom-biosciences-and-hospices-civils-de-lyon-announce-clinical-collaboration-in-recurrent-clostridioides-difficile-infection
https://www.exeliombio.com/news/exeliom-biosciences-announces-that-the-independent-data-monitoring-committee-idmc-recommends-continuation-of-phase-1-clinical-trial-of-exl01-in-crohns-disease
https://www.exeliombio.com/news/new-review-on-faecalibacterium-published-in-fems-microbiology-reviews-explores-its-potential-for-human-health
https://www.exeliombio.com/news/exeliom-biosciences-announces-series-a-extension-and-final-closing-with-total-of-eu24-million-to-progress-the-clinical-development-of-its-lead-candidate-in-immuno-oncology-and-infectious-diseases
https://www.exeliombio.com/news/satt-paris-saclay-and-exeliom-biosciences-sign-license-option-agreement-to-develop-breakthrough-recombinant-protein-targeting-tryptophan-metabolism
https://www.exeliombio.com/news/exeliom-biosciences-announces-first-patient-enrolled-in-phase-1-study-for-the-maintenance-in-remission-in-adult-patients-with-mild-to-moderate-crohns-disease
https://www.exeliombio.com/news/exeliom-biosciences-announces-approval-of-clinical-trial-application-from-the-belgian-agency-for-single-strain-live-biotherapeutic-exl01-faecalibacterium-prausnitzii-for-the-treatment-of-crohns-disease
https://www.exeliombio.com/news/exeliom-biosciences-joins-paris-biotech-sante-incubator
https://www.exeliombio.com/news/exeliom-biosciences-has-been-awarded-a-2-5meu-h2020-accelerator-program-grant-from-the-european-innovation-council
http://www.rebiotix.com/wp-content/uploads/lack-of-association-patient-demographics-outcomes-punch-cd2-controlled-trial-recurrent-clostridium-difficile-infection-poster.pdf
https://openbiome.org/features/
https://www.rebiotix.com/wp-content/uploads/rapid-restoration-bile-acid-compositions-after-treatment-rbx2660-recurrent-clostridioides-difficile-infectionresults-punch-cd3-phase-3-trial-poster.pdf
https://www.rebiotix.com/wp-content/uploads/effect-microbiota-based-investigational-drug-rbx2660-gut-microbiome-resistome-revealed-placebo-controlled-clinical-trial.pdf
https://www.rebiotix.com/wp-content/uploads/five-rbx2660-trials-demonstrat-efficacy-recurrent-c-difficile-infection-id-week-2021.pdf
https://valneva.com/press-release/valneva-to-participate-in-investor-conferences-in-the-united-states-and-europe-in-september-2023/
https://valneva.com/press-release/health-canada-accepts-valnevas-chikungunya-vaccine-license-application-for-review/?lang=fr
https://valneva.com/press-release/valneva-announces-the-availability-of-documentation-for-its-shareholder-meeting/
https://valneva.com/press-release/valneva-to-present-and-hold-investor-meetings-at-upcoming-conferences-in-june/?lang=fr
https://valneva.com/press-release/valneva-files-for-chikungunya-vaccine-authorization-with-health-canada/
https://crestonepharma.com/category/press-releases/
https://ondinebio.com/steriwave-featured-on-bbc-news/
https://ondinebio.com/steriwave-authorized-for-use-by-hca-uk/
https://www.acurxpharma.com/news-media/press-releases/detail/75/acurx-pharmaceuticals-inc-reports-fourth-quarter-and-full
https://www.exeliombio.com/news/exeliom-biosciences-is-awarded-i-lab2018-from-bpifrance
https://valneva.com/press-release/valneva-reports-first-quarter-2023-financial-results-and-provides-corporate-updates/?lang=fr
https://www.biomicamed.com/press-releases/biomica-to-present-at-the-american-society-of-clinical-oncology-asco-2024-annual-meeting/
https://www.enterobiotix.com/news/enterobiotix-at-microbiome-movement-dds-boston-2024
https://www.enterobiotix.com/news/enterobiotix-at-bio-europe-2024-stockholm
https://www.enterobiotix.com/news/enterobiotix-at-lsx-world-congress-2024
https://www.enterobiotix.com/news/enterobiotix-at-bio-international-convention-2024
https://www.enterobiotix.com/news/enterobiotix-at-bioequity-europe-2024
https://www.enterobiotix.com/news/enterobiotix-at-bio-future-new-york-2024
https://www.enterobiotix.com/news/enterobiotix-at-biotrinitylondon-2024
https://www.exeliombio.com/news/exeliom-biosciences-opens-pilot-manufacturing-unit-for-live-biotherapeutics-lbps
https://verbbiotics.com/redefining-the-gut-microbiome/
https://valneva.com/press-release/valneva-to-participate-in-investor-conferences-in-the-united-states-and-europe-in-september-2023/?lang=fr
https://valneva.com/press-release/valneva-to-present-on-its-chikungunya-vaccine-candidate-and-host-a-roundtable-at-the-23rd-world-vaccine-congress-in-washington-d-c/?lang=fr
https://valneva.com/press-release/valneva-reports-full-year-2022-results-and-provides-corporate-updates/?lang=fr
https://ondinebio.com/32-fewer-ssis-after-steriwave-replaced-mupirocin/
https://www.acurxpharma.com/news-media/press-releases/detail/77/acurx-pharmaceuticals-announces-presentation-of
https://www.biomicamed.com/press-releases/biomica-raises-20-million-in-a-financing-round-to-advance-its-pipeline-of-microbiome-based-therapeutics/
https://www.biomicamed.com/press-releases/biomica-ceo-to-participate-in-an-industry-panel-discussion-at-microbiome-connect-usa-2022-summit/
https://www.exeliombio.com/news/exeliom-biosciences-is-awarded-1-8meu-deeptech-grant-from-bpifrance-to-advance-its-lead-program
https://openbiome.org/about-us/annual-reports-financials/
https://www.ferring.com/media/press-releases/
https://valneva.com/press-release/valneva-provides-clinical-and-regulatory-updates-for-its-covid-19-vaccine-vla2001/?lang=fr
https://valneva.com/press-release/valneva-to-present-at-the-cowen-43rd-annual-healthcare-conference/
https://valneva.com/press-release/valneva-to-present-at-the-cowen-43rd-annual-healthcare-conference/?lang=fr
https://valneva.com/press-release/valneva-to-present-at-the-cowen-43rd-annual-healthcare-conference/?lang=de
https://valneva.com/press-release/pfizer-and-valneva-issue-update-on-phase-3-clinical-trial-evaluating-lyme-disease-vaccine-candidate-vla15/
https://valneva.com/press-release/valneva-completes-enrollment-for-adolescent-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/?lang=fr
https://valneva.com/press-release/valneva-completes-enrollment-for-adolescent-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/
https://valneva.com/press-release/valneva-completes-enrollment-for-adolescent-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/?lang=de
https://ondinebio.com/new-study-confirms-nose-is-key-source-of-infection/
https://ondinebio.com/corporate-and-trading-update/
https://ondinebio.com/steriwave-in-first-australian-hospital/
https://www.biomicamed.com/press-releases/biomica-appoints-professor-gal-markel-to-companys-scientific-advisory-board/
https://www.smmttx.com/wp-content/uploads/2023/10/2021_PR_0809_Q2-2021-Financial-Results-_-FINAL.pdf
https://www.acurxpharma.com/news-media/press-releases/detail/78/acurx-pharmaceuticals-announces-presentation-of
https://www.acurxpharma.com/news-media/press-releases?page=2
https://www.biomicamed.com/press-releases/biomica-announces-successful-enrollment-of-first-patient-in-its-phase-i-study-of-microbiome-based-immuno-oncology-drug/
https://www.enterobiotix.com/news/enterobiotix-ceo-features-in-forbes-30-under-30-2022
https://www.enterobiotix.com/news/category/Events
https://www.enterobiotix.com/news/interview-with-enterobiotix-ceo-dr-james-mcilroy
https://www.smmttx.com/wp-content/uploads/2023/10/Blue_20210515-_-Q1-2021-Financial-Results-_-FINAL.pdf.pdf
https://verbbiotics.com/the-highest-utilization-of-diet-and-probiotics/
https://verbbiotics.com/verb-labs/
https://valneva.com/press-release/valneva-completes-bla-submission-to-u-s-fda-for-its-single-shot-chikungunya-vaccine-candidate/?lang=fr
https://valneva.com/press-release/valneva-to-conduct-investor-meetings-during-the-j-p-morgan-healthcare-conference-and-oddo-bhf-forum/
https://openbiome.org/microbiome-education/whitepapers2-0/
https://ondinebio-staging-oct-21-2021-clonedfortesting.mystagingwebsite.com/category/steriwave/
https://ondinebio.com/ecdc-report-shows-hais-are-increasing-antibiotic-use/
https://www.acurxpharma.com/news-media/press-releases/detail/80/acurx-announces-successful-fda-end-of-phase-2-meeting-and
https://www.exeliombio.com/news/exeliom-biosciences-announces-three-phase-ii-clinical-trials-in-immuno-oncology-with-lead-candidate-combined-with-immune-checkpoint-inhibitors
https://valneva.com/press-release/valneva-reports-positive-12-month-antibody-persistence-data-for-single-shot-chikungunya-vaccine-candidate/?lang=fr
https://valneva.com/press-release/valneva-appoints-dipal-patel-as-chief-commercial-officer/?lang=de
https://www.enterobiotix.com/news/enterobiotix-at-bioequity-2023
https://www.exeliombio.com/news/exeliom-biosciences-joins-wilco-incubator
https://valneva.com/press-release/valneva-announces-launch-of-global-offering-of-american-depositary-shares-and-ordinary-shares/?lang=de
https://ondinebio.com/category/photodisinfection/
https://www.biomicamed.com/press-releases/biomica-to-present-at-the-asco-2022-annual-meeting/
https://www.biomicamed.com/press-releases/biomica-to-present-at-jefferies-microbiome-based-therapeutics-summit-on-april-22nd-2021-virtual-conference/
https://www.biomicamed.com/press-releases/biomica-announces-participation-at-the-crohns-colitis-congress-january-21-24-2021-virtual-conference/
https://www.biomicamed.com/press-releases/biomica-announces-initiation-of-large-scale-production-of-live-bacterial-product-lbp-candidate-consortium-in-its-immuno-oncology-program/
https://www.biomicamed.com/press-releases/biomica-reports-positive-preliminary-results-in-animal-studies-in-its-immuno-oncology-program/
https://www.biomicamed.com/press-releases/biomica-to-collaborate-with-weizmann-institute-of-science-to-develop-a-selective-treatment-against-antibiotic-resistant-bacteria/
https://www.biomicamed.com/press-releases/biomica-announces-advancement-to-pre-clinical-studies-in-its-inflammatory-bowel-disease-program/
https://www.enterobiotix.com/news/number-2-trademark-fully-registered
https://www.smmttx.com/app/uploads/2018/12/Slingshot-Insights-Transcript-Dr-Martinello.pdf
https://valneva.com/press-release/valneva-confirms-who-recommendations-for-its-inactivated-covid-19-vaccine/?lang=de
https://valneva.com/press-release/valneva-reports-h1-2022-results-and-provides-corporate-updates/?lang=fr
https://valneva.com/press-release/valneva-confirms-amendment-of-advance-purchase-agreement-with-european-commission-for-valnevas-inactivated-covid-19-vaccine/?lang=de
https://valneva.com/press-release/valneva-announces-successful-outcome-of-its-agm-and-appointment-of-two-new-supervisory-board-members/?lang=fr
https://www.biomicamed.com/press-releases/biomica-evogenes-newly-established-subsidiary-announces-therapeutic-areas-of-focus/
https://valneva.com/press-release/valneva-announces-settlement-agreement-with-the-uk-government/?lang=de
https://openbiome.org/feature/the-death-of-a-patient-and-the-future-of-fecal-transplants/
https://openbiome.org/global-health/the-global-microbiome-conservancy-gmbc/
https://ondinebio.com/investors/reports-documentation/
https://www.acurxpharma.com/news-media/press-releases/detail/79/acurx-pharmaceuticals-inc-reports-first-quarter-2024
https://www.acurxpharma.com/news-media/press-releases/detail/76/acurx-pharmaceuticals-inc-to-discuss-first-quarter-2024
https://valneva.com/press-release/valneva-and-pfizer-report-positive-phase-2-pediatric-data-for-lyme-disease-vaccine-candidate/?lang=de
https://valneva.com/press-release/valneva-announces-resumption-of-trading-of-its-ordinary-shares-on-euronext-paris/?lang=de
https://valneva.com/press-release/valneva-receives-initial-chmp-assessment-of-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/?lang=fr
https://valneva.com/press-release/valneva-and-pfizer-report-further-positive-phase-2-data-for-lyme-disease-vaccine-candidate/?lang=de
https://valneva.com/press-release/valneva-announces-initiation-of-adolescent-phase-3-trial-for-its-single-shot-chikungunya-vaccine-candidate/
https://www.exeliombio.com/news/nextbiotix-becomes-exeliom-biosciences
https://verbbiotics.com/functional-beverages-why-everyones-talking-about-them/
https://valneva.com/press-release/valneva-signs-purchase-agreement-with-european-commission-for-its-inactivated-covid-19-vaccine-vla2001/?lang=fr
https://valneva.com/press-release/valneva-continues-ongoing-discussions-with-the-european-commission-for-inactivated-covid-19-vaccine-candidate/
https://valneva.com/press-release/valneva-continues-ongoing-discussions-with-the-european-commission-for-inactivated-covid-19-vaccine-candidate/?lang=fr
https://openbiome.org/wp-content/uploads/2022-financials-form-990.pdf
https://openbiome.org/feature/i-visited-americas-first-poop-bank/
https://openbiome.org/feature/a-qa-with-openbiome-from-the-power-of-poop/
https://openbiome.org/administering-physician/
https://openbiome.org/global-health/the-global-microbiome-conservancy-gmbc/gmbc-collection/
https://openbiome.org/wp-content/uploads/2020-OpenBiome-Annual-Report.pdf
https://openbiome.org/about-us/mission/
https://ondinebio.com/steriwave-now-available-through-nhs-supply-chain/
https://ondinebio.com/category/steriwave/
https://verbbiotics.com/reaching_your_bacterial_genetic_potential/
https://www.paratekpharma.com/investor-relations/press-release?i=99729
https://valneva.com/press-release/valneva-completes-phase-3-trial-recruitment-for-its-inactivated-covid-19-vaccine-candidate/
https://valneva.com/press-release/valneva-reports-q1-2021-financial-results-and-business-update/
https://valneva.com/press-release/valneva-announces-new-59-million-ixiaro-supply-contract-with-us-government/
https://valneva.com/press-release/2010-on-target-strong-revenue-growth-56-year-end-cash-e42-5m-2011-objectives-eb66-technology-6-to-7-new-licenses-humalex-technology-1-new-partnership-agreement-and-development-of-pro/?lang=fr
https://openbiome.org/feature/universidad-nacional-litoral-and-conicet-in-santa-fe-launches-seminal-study-of-human-microbiome-in-argentina-in-partnership-with-us-nonprofit-openbiome/
https://openbiome.org/microbiome-education/webinars/
https://openbiome.org/about-us/
https://www.exeliombio.com/news/exeliom-biosciences-collaborates-with-remind-in-maintain-pop-study
https://microbiotica.com/pipeline/
https://microbiotica.com/milner-institute-symposium-2024/
https://microbiotica.com/working-here/
https://microbiotica.com/platform/
https://microbiotica.com/cookie-notice/
https://microbiotica.com/pipeline/manufacturing/
https://microbiotica.com/about/team/
https://microbiotica.com/about/
https://microbiotica.com/events/
https://microbiotica.com/press-releases/
https://www.serestherapeutics.com/wp-content/uploads/2021/10/Sims-M-Diagnostic-Testing-ID-Week-2021-Poster-658.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=133376
https://www.paratekpharma.com/investor-relations/press-release?i=131794
https://www.paratekpharma.com/investor-relations/press-release?i=103112
https://www.paratekpharma.com/investor-relations/press-release?i=94268
https://www.paratekpharma.com/investor-relations/press-release?i=102815
https://www.acurxpharma.com/news-media/press-releases?page=8
https://www.enterobiotix.com/news/enterobiotix-appoints-david-lawrence-to-its-board-of-directors
https://microbiotica.com/microbiotica-to-present-positive-update-on-manufacturing-progress-of-its-live-biotherapeutic-products-for-forthcoming-melanoma-and-ulcerative-colitis-clinical-studiess/
https://www.paratekpharma.com/investor-relations/press-release?i=99389
https://openbiome.org/publication/the-association-of-stool-donor-diet-on-microbial-profile-and-clinical-outcomes-of-fecal-microbiota-transplantation-in-clostridium-difficile-infection/
https://ondinebio.com/tag/2024/page/2/
https://ondinebio.com/category/news/
https://ondinebio.com/tag/antimicrobial-resistance/
https://ondinebio.com/ondine-cmo-interviewed-in-european-biopharmaceutical-review-2/
https://ondinebio.com/media-resources/
https://www.acurxpharma.com/news-media/press-releases/detail/81/acurx-pharmaceuticals-announces-presentation-of
https://www.enterobiotix.com/news/enterobiotix-ceo-completes-500-pull-ups-and-press-ups-to-raise-funds-for-the-brain-charity
https://www.rebiotix.com/wp-content/uploads/ferring-landmark-research-microbiota-live-biotherapeutic-rbx2660-idweek-2021.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=135844
https://www.paratekpharma.com/investor-relations/press-release?i=130169&utm_source=social&utm_medium=xandlinkedin&utm_campaign=lightbostrompromotions
https://www.enterobiotix.com/news/enterobiotix-appoints-elmar-schnee
https://verbbiotics.com/the-ecology-of-the-human-gut/
https://openbiome.org/global-health/the-global-microbiome-conservancy-gmbc/science-and-ethics-advisory-board/
https://microbiotica.com/partnering/
https://www.paratekpharma.com/investor-relations/press-release?i=136501
https://www.paratekpharma.com/investor-relations/press-release?i=119207
https://openbiome.org/wp-content/uploads/OpenBiome-Malnutrition-Case-for-Support.pdf
https://openbiome.org/wp-content/uploads/IntroToFMT-1.pdf
https://openbiome.org/publication/fecal-microbiota-transplantation-for-severe-or-fulminant-clostridioides-difficile-infection/
https://openbiome.org/feature/a-clarification-about-fecal-microbiota-transplantation/
https://www.acurxpharma.com/news-media/press-releases/detail/84/acurx-pharmaceuticals-inc-reports-second-quarter-2024
https://www.smmttx.com/pressrelease/summit-therapeutics-inc-reports-financial-results-and-operational-progress-for-the-second-quarter-ended-june-30-2022/
https://www.smmttx.com/wp-content/uploads/2023/10/Blue_2020_PR_10-Duggan-Exec-Chairman-FINAL.pdf
https://www.smmttx.com/wp-content/uploads/2023/10/Blue_2020_RNS_03-BARDA-contract-expansion-FINAL.pdf
https://verbbiotics.com/verb-labs/page/2/?cat=all&et_blog
https://www.paratekpharma.com/investor-relations/press-release?i=126798
https://valneva.com/press-release/virbac-exercises-its-option-for-a-commercial-licence-agreement-to-use-vivalis-ebx-platform-for-the-production-of-several-vaccines/
https://ondinebio.com/technology/
https://ondinebio.com/leeds-teaching-hospitals-nhs-trust-to-use-steriwave/
https://ondinebio.com/news/
https://ondinebio.com/author/webmaster/
https://www.enterobiotix.com/news/enterobiotix-ceo-features-on-beyond-biotech-podcast
https://ondinebio.com/solutions/steriwave-healthcare/
https://www.acurxpharma.com/news-media/press-releases/detail/83/uspto-grants-acurx-pharmaceuticals-new-patent-for
https://microbiotica.com/microbiotica-to-present-positive-update-on-manufacturing-progress-of-its-live-biotherapeutic-products-for-forthcoming-melanoma-and-ulcerative-colitis-clinical-studies/
https://verbbiotics.com/author/brookeb/page/2/
https://ondinebio.com/steriwave-in-all-british-columbia-health-authorities/
https://microbiotica.com/microbioticas-microbiome-medicines-in-melanoma-and-ulcerative-colitis-gain-regulatory-approvals-in-eu-and-uk-for-phase-1b-studies/
https://www.rebiotix.com/tag/press-releases/
https://www.paratekpharma.com/investor-relations/press-release?i=93335
https://valneva.com/press-release/valneva-announces-signing-of-an-exclusive-license-agreement-on-eb66-cell-line-for-human-and-veterinary-vaccines-in-peoples-republic-of-china/?lang=de
https://openbiome.org/wp-content/uploads/Evaluating-Patients-cdiff-1.pdf
https://www.mgb-biopharma.com/category/news/?utm_source=pharminews.com&utm_medium=website&utm_campaign=pharmiweb
https://ondinebio.com/steriwave-redirect/
https://www.acurxpharma.com/news-media/press-releases/detail/82/acurx-pharmaceuticals-inc-to-discuss-second-quarter-2024
https://www.enterobiotix.com/news/enterobiotix-secures-215m-series-a-to-advance-microbiome-drug-pipeline
https://www.rebiotix.com/wp-content/uploads/interim-phase-3-results-open-label-study-microbiota-based-live-biotherapeutic-rbx2660.pdf
https://www.rebiotix.com/wp-content/uploads/efficacy-rbx2660-vs-placebo-reduce-recurrence-c-difficile-infection.pdf
https://openbiome.org/feature/openbiome-voluntarily-suspends-fmt-shipments/
https://ondinebio.com/category/covid-19/
https://www.enterobiotix.com/news/enterobiotix-raises-more-than-21m-in-series-a
https://www.smmttx.com/wp-content/uploads/2023/10/Blue_2021_PR_0701_Upcoming-Conference-ECCMID-_-FINAL.pdf
https://openbiome.org/feature/important-update-fda-allows-openbiome-to-continue-fmt-distribution-through-october-31st/
https://openbiome.org/wp-content/uploads/Current-Evidence-Clinical-cdiff-2.pdf
https://ondinebio.com/molnlycke-and-ondine-join-forces-against-hais/
https://www.acurxpharma.com/news-media/press-releases/detail/87/acurx-announces-additional-ibezapolstat-ph2b-results-in-cdi
https://www.smmttx.com/wp-content/uploads/2023/12/2011interimreportfinal.pdf
https://www.smmttx.com/wp-content/uploads/2023/12/Summit-Annual-Report-2013-14.pdf
https://openbiome.org/register/
https://ondinebio.com/collaboration-advances-steriwave-for-icu-market/
https://ondinebio.com/ondine-secures-c5-million-financing/
https://www.acurxpharma.com/news-media/presentations
https://www.acurxpharma.com/news-media/press-releases/detail/85/acurx-pharmaceuticals-announces-participation-at-the-h-c
https://microbiotica.com/novel-biotherapeutic-to-be-tested-in-ulcerative-colitis-2/
https://microbiotica.com/could-microbiome-drugs-be-the-key-to-unlocking-checkpoint-inhibitors-potential/
https://microbiotica.com/event/
https://www.rebiotix.com/about-rebiotix/stool-donor-program/
https://www.rebiotix.com/wp-content/uploads/Ferring-Receives-Positive-Vote-US-FDA-ACM-RBX2660.pdf
https://www.smmttx.com/wp-content/uploads/2023/10/Blue_2020_PR_16-Intention-to-Redomicile-FINAL.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=103624
https://www.smmttx.com/wp-content/uploads/2023/12/2012interimreportfinal-1.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=114906
https://openbiome.org/publication/oral-fecal-microbiota-transplant-capsules-are-safe-and-effective-for-recurrent-clostridioides-difficile-infection/
https://www.acurxpharma.com/news-media/press-releases/detail/89/acurx-pharmaceuticals-announces-participation-at-the
https://www.acurxpharma.com/news-media/press-releases/detail/88/acurx-pharmaceuticals-to-discuss-third-quarter-2024
https://www.rebiotix.com/wp-content/uploads/rebiotix-completes-enrollment-pivotal-phase-3-clinical-trial-microbiota-based-rbx2660.pdf
https://ondinebio.com/steriwave-receives-uae-regulatory-approval/
https://www.rebiotix.com/wp-content/uploads/rebiotix-discuss-microbiome-product-development-challenges-regulation-microbiome-movement.pdf
https://www.paratekpharma.com/investor-relations/press-release?i=139181
https://ondinebio.com/kings-college-hospital-to-run-steriwave-pilot/
https://ondinebio.com/tag/photodisinfection/
https://www.enterobiotix.com/news/enterobiotix-completes-new-manufacturing-facility-focused-on-gut-microbiome-therapies
https://microbiotica.com/microbiotica-announces-first-patient-dosed-in-its-international-phase-1b-trial-melody-1-of-mb097-precision-microbiome-co-therapy-in-advanced-melanoma/
https://www.rebiotix.com/wp-content/uploads/investigational-microbiota-based-therapies-recurrent-c-diff-highlighted-ddw-2019.pdf
https://openbiome.org/publication/effect-of-antibiotic-pretreatment-on-bacterial-engraftment-after-fecal-microbiota-transplant-fmt-in-ibs-d/
https://ondinebio.com/ondine-continues-commercial-growth/
https://microbiotica.com/bio-europe-2024/
https://microbiotica.com/uk-pitching-day/
https://microbiotica.com/esmo-2024/
https://www.rebiotix.com/wp-content/uploads/successful-response-microbiota-based-drug-rbx2660-patients-recurrent-clostridium-difficile-infection-microbiome-profile-abstract.pdf
https://www.smmttx.com/wp-content/uploads/2023/10/2022_PR_1003_New-Director-Booth-_-FINAL.pdf
https://www.smmttx.com/wp-content/uploads/2023/10/2021_PR_1008_New-Director-_-FINAL.pdf
https://verbbiotics.com/verb-labs/page/2/?et_blog
https://verbbiotics.com/verb-labs/microbiome-health/
https://www.paratekpharma.com/investor-relations/press-release?i=140102
https://openbiome.org/publication/do-clinical-factors-affect-microbial-engraftment-after-fecal-microbiota-transplantation-in-recurrent-clostridium-difficile-infection/
https://openbiome.org/feature/inaugural-openbiome-global-health-study-to-address-severe-acute-malnutrition/
https://openbiome.org/feature/september-25-panel-on-microbiome-science-at-un-science-summit-to-offer-new-thinking-and-promote-action-to-address-childhood-malnutrition/
https://openbiome.org/publication/stool-banking-for-fecal-microbiota-transplantation-methods-and-operations-at-a-large-stool-bank/
https://openbiome.org/feature/openbiome-applauds-new-aga-guidelines-on-fecal-microbiota-transplants/
https://ondinebio.com/ondine-biomedicals-c-16-million-fundraise-enables-a-q4-2024-start-of-its-pivotal-phase-3-us-trial/
